Bioprocess Automation Market Size & Growth Forecast 2027–2036, By Segments (Product & Service, Process Stage, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Bioprocess Automation Market size stood at USD 9.54 billion in 2026 and is predicted to grow at a 13.31% CAGR from 2027 to 2036, attaining USD 33.28 billion by 2036. The industry revenue for 2027 is estimated at USD 10.64 billion.
Get more details on this report
Request Free Sample ReportBioprocess Automation Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 45.35% global market share, supported by established biotechnology capabilities, advanced biopharmaceutical manufacturing, and demand for consistent, efficient production of complex biological products.
- Asia Pacific is the fastest-growing region, driven by expanding biopharmaceutical manufacturing capacity, investments in biotechnology infrastructure, and rising demand for biologics, vaccines, biosimilars, and advanced therapies.
Segment Momentum
- Process automation hardware accounted for 32.79% market share in 2026, reflecting its essential role in monitoring and controlling critical process parameters. Sensors, controllers, and actuators help manufacturers maintain consistent conditions and improve production reliability.
- Software and control systems are the fastest-growing product and service segment, driven by demand for centralized monitoring, data management, and advanced analytics. These platforms help manufacturers identify process deviations, optimize operations, and improve production visibility.
Market Expansion Drivers
- Increasing biopharmaceutical production and biologics demand.
- Adoption of automated and continuous bioprocessing technologies.
- Integration of AI and digital twins for process optimization in bioprocessing.
Leading Market Participants
- Major players in the bioprocess automation market include Siemens (Germany), Emerson (USA), ABB (Switzerland), Rockwell Automation (USA), Sartorius (Germany), Thermo Fisher Scientific (USA), Danaher (USA), Endress+Hauser (Switzerland), Yokogawa Electric (Japan), Honeywell (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 9.54 billion
- 2027 Estimated Market Size: USD 10.64 billion
- Projected Market Size: USD 33.28 billion by 2036
- Growth Forecast: 13.31% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product & Service (Process Automation Hardware) | Process Stage (Upstream) | End Use (Pharmaceutical & Biotech Manufacturers)
- Emerging Opportunity Segment: Product & Service (Software & Control Systems) | Process Stage (Upstream) | End Use (Pharmaceutical & Biotech Manufacturers)
Market Growth Drivers and Industry Trends
Increasing biopharmaceutical production and biologics demand
The growing production of biologics, vaccines, cell and gene therapies, and other advanced biopharmaceutical products is increasing demand for automated bioprocessing solutions that can support complex manufacturing workflows. Biologics often require tightly controlled processing conditions, precise monitoring, and consistent handling across multiple stages, making automation increasingly important for maintaining product quality and process reproducibility. As manufacturers expand production capabilities and adopt more sophisticated therapeutic modalities, automated systems are gaining importance in upstream and downstream processing, media preparation, purification, sampling, and process monitoring. The need to improve manufacturing consistency while managing complex production requirements is therefore supporting broader adoption of bioprocess automation technologies.
Adoption of automated and continuous bioprocessing technologies
The shift toward automated and continuous bioprocessing is accelerating demand for technologies that can improve process consistency, reduce manual intervention, and enable more efficient use of manufacturing resources. Continuous processing allows certain production activities to operate with greater integration between individual stages, while automation enables real-time monitoring and precise control of critical process parameters. These capabilities can help manufacturers minimize variability, streamline workflows, and improve operational flexibility while supporting stringent quality requirements. Increasing interest in flexible manufacturing platforms and more efficient production models is encouraging biopharmaceutical facilities to incorporate automated control systems, integrated equipment, and continuous processing technologies into modern production environments.
Integration of AI and digital twins for process optimization in bioprocessing
The integration of artificial intelligence, machine learning, and digital twin technologies is creating new opportunities to optimize bioprocessing operations and improve decision-making throughout manufacturing workflows. AI-based systems can analyze complex process data to identify patterns, detect deviations, and support predictive monitoring, while digital twins can simulate process conditions and help manufacturers evaluate potential changes before implementing them in physical production environments. These technologies are increasingly valuable for understanding process behavior, improving parameter control, and identifying opportunities to enhance yield and consistency. As bioprocessing becomes more data-intensive, the combination of automation with intelligent analytics is supporting the development of more adaptive, predictive, and digitally connected manufacturing environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing biopharmaceutical production and biologics demand | 5% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Adoption of automated and continuous bioprocessing technologies | 4% | Medium term (2–5 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Moderate |
| Integration of AI and digital twins for process optimization in bioprocessing | 4% | Long term (5+ yrs) | North America; Asia Pacific | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The bioprocess automation market in North America held the largest regional share, accounting for 45.35% of the global market. The region’s leading position is supported by an established biotechnology industry, advanced biopharmaceutical manufacturing infrastructure, and substantial emphasis on process consistency and production efficiency. Biopharmaceutical manufacturers increasingly use automated systems to monitor critical process parameters, control manufacturing operations, and improve reproducibility across upstream and downstream processing activities. Automation technologies, including process control systems, sensors, data acquisition platforms, and integrated manufacturing software, help reduce manual intervention while strengthening operational oversight. The growing complexity of biologics, vaccines, and cell and gene therapies is further increasing the need for precise and reliable process management. Established research capabilities and investment in modern manufacturing facilities also support the adoption of scalable automation solutions that help maintain product quality and compliance with stringent manufacturing requirements.
Asia Pacific (Fastest-Growing Region)
The bioprocess automation market in Asia Pacific is expected to grow at the fastest rate, driven by expanding biopharmaceutical manufacturing capacity, increasing investment in biotechnology infrastructure, and rising demand for biologics and advanced therapies. Pharmaceutical manufacturers across the region are strengthening production capabilities to support domestic healthcare requirements and participate more extensively in global biopharmaceutical supply chains. The development of new manufacturing facilities is creating opportunities for automated bioreactors, process monitoring systems, and integrated control platforms that improve consistency and operational efficiency. Growing interest in biosimilars, vaccines, recombinant proteins, and other biological products is further increasing the importance of reliable manufacturing processes. In addition, improvements in technical expertise and greater emphasis on international quality standards are encouraging the adoption of advanced automation technologies. The need to manage production costs while maintaining process reliability is shaping purchasing decisions, particularly among manufacturers expanding their bioprocessing operations.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Scale-Up AutomationThe U.S. prioritizes bioprocess automation that supports higher-throughput manufacturing, consistent process control, and faster movement from development to commercial production. Demand is reinforced by biopharmaceutical companies seeking integrated automation across upstream processing, analytics, data management, and quality workflows.
Germany 🇩🇪
Integrated ManufacturingGermany emphasizes tightly integrated and precision-engineered automation for bioprocessing environments. Market activity centers on connecting equipment, process analytics, and digital control systems while supporting efficient manufacturing, reproducibility, and compliance across established pharmaceutical and biotechnology production operations.
Japan 🇯🇵
Quality-Controlled AutomationJapan's bioprocess automation priorities are closely linked to manufacturing reliability, process consistency, and stringent quality management. Adoption is focused on reducing manual intervention and improving control across complex biologics production, with automation supporting efficient operations within established pharmaceutical manufacturing environments.
South Korea 🇰🇷
Biologics Production ScalingSouth Korea focuses on automation capabilities that support the expansion and efficient operation of large-scale biologics manufacturing. Bioprocess suppliers are addressing demand for scalable systems, real-time process monitoring, and integrated digital workflows that help manufacturers improve productivity and maintain consistent production quality.
France 🇫🇷
Flexible Bioprocess OperationsFrance is prioritizing bioprocess automation that can support flexible biologics production and modernization of pharmaceutical manufacturing operations. Automation investments increasingly focus on improving process visibility, reducing manual workflows, and connecting production systems with analytical and quality-control activities.
Italy 🇮🇹
Production ModernizationItaly's market is shaped by pharmaceutical manufacturers modernizing production infrastructure and strengthening operational consistency. Bioprocess automation demand centers on adaptable equipment, improved process monitoring, and digital control solutions that can be incorporated into both established manufacturing sites and specialized biologics operations.
Bioprocess Automation Market Share (%), by Product & Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct & Service Segment Analysis: Process Automation Hardware (Largest Segment) vs Software & Control Systems (Fastest-Growing Segment)
The process automation hardware segment accounted for 32.79% share of the bioprocess automation market in 2026, supported by the essential role of automation hardware in controlling, monitoring, and optimizing bioprocessing operations. Equipment such as sensors, controllers, actuators, and other automation components enables manufacturers to maintain consistent operating conditions and improve process reliability across complex production environments. Increasing adoption of automated manufacturing practices is encouraging bioprocessing facilities to modernize equipment and reduce dependence on manual intervention, particularly where precise control of critical process parameters is required. In addition, the growing complexity of biopharmaceutical production and the need for reproducible manufacturing outcomes are strengthening demand for reliable automation hardware. Integration with broader digital manufacturing infrastructure is also enhancing the ability of hardware systems to provide real-time process information and support efficient production management.
The software & control systems segment is expected to register the fastest growth across the product and service landscape, driven by increasing demand for intelligent process monitoring, centralized control, data management, and advanced analytics. Software platforms can connect automation components across bioprocessing workflows, enabling manufacturers to monitor process conditions, identify deviations, optimize operations, and improve overall production visibility. The growing adoption of data-driven manufacturing is further increasing the importance of software capable of integrating process information and supporting automated decision-making. In addition, advances in analytics, connectivity, and digital control technologies are helping manufacturers improve process consistency while reducing operational inefficiencies. As bioprocessing facilities increasingly transition toward connected and digitally managed production environments, software and control systems are expected to gain greater importance in automation strategies.
Process Stage Segment Analysis: Upstream (Largest & Fastest-Growing Segment)
The upstream segment accounted for 37.7% share of the bioprocess automation market in 2026, reflecting the critical importance of automated control during cell culture, fermentation, media preparation, and other early-stage bioprocessing activities. Upstream operations require precise management of parameters such as temperature, ph, dissolved oxygen, nutrient conditions, and agitation to maintain optimal biological performance and achieve consistent production outcomes. Automation enables continuous monitoring and adjustment of these variables, reducing manual intervention and helping manufacturers maintain stable process conditions. The increasing complexity of biologics manufacturing is further encouraging the adoption of automation technologies that can improve reproducibility and process visibility. In addition, the growing emphasis on reducing batch variability, improving productivity, and maintaining stringent quality requirements is supporting the integration of automated monitoring and control throughout upstream workflows. As manufacturers expand bioprocessing capacity and seek greater process efficiency, upstream automation is expected to remain a major area of demand.
End Use Segment Analysis: Pharmaceutical & Biotech Manufacturers (Largest & Fastest-Growing Segment)
The pharmaceutical & biotech manufacturers segment accounted for 39.14% share of the bioprocess automation market in 2026, driven by the increasing need for efficient, consistent, and scalable manufacturing processes for biologics and other advanced therapies. Pharmaceutical and biotechnology manufacturers rely on automation to monitor critical process parameters, maintain production consistency, improve operational efficiency, and support compliance with stringent quality requirements. The expansion of biologics development and manufacturing is creating greater demand for automated systems capable of managing increasingly sophisticated production workflows. Automation also enables manufacturers to reduce manual intervention, improve data traceability, and identify process deviations more rapidly, supporting stronger quality control throughout production. Furthermore, the shift toward flexible and scalable manufacturing approaches is encouraging investment in integrated automation technologies that can adapt to changing production requirements. As pharmaceutical and biotechnology companies continue to strengthen manufacturing capabilities and adopt more digitally connected production environments, this end-use segment is expected to maintain strong momentum.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product & Service | Automation Consumables & Accessories, Process Automation Hardware, Software & Control Systems, Integrated & Turnkey Solutions, Services & Support | Process Automation Hardware | Software & Control Systems |
| Process Stage | Upstream, Downstream, Process Development & Scale-up, Fill/Finish & Packaging Automation, Quality Control & PAT | Upstream | Upstream |
| End Use | Pharmaceutical & Biotech Manufacturers, CDMOs & CMOs, Academic & Research Institutions, Contract Testing & Analytical Labs, Others | Pharmaceutical & Biotech Manufacturers | Pharmaceutical & Biotech Manufacturers |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Integration and scalability are central to competition in the bioprocess automation market, as manufacturers seek reliable control across increasingly connected production environments. Single-use bioreactors and integrated sensors can simplify operations, but their value depends on measurement consistency, calibration, and compatibility with existing control systems. Process Analytical Technology (PAT) extends these capabilities by translating process measurements into actionable information, provided analytical models and data are adequately validated. Meanwhile, scalable control architectures and SCADA connectivity enable coordination across equipment, instruments, and manufacturing systems, supporting traceability as facilities expand. Continuous biomanufacturing adds further complexity by requiring synchronized process stages and timely responses to deviations. Vendors therefore differentiate through interoperability, dependable process monitoring, and validated control capabilities that support consistent product quality without introducing unnecessary operational complexity or consumable costs.
Top players in the bioprocess automation market:
- Siemens (Germany)
- Emerson (USA)
- ABB (Switzerland)
- Rockwell Automation (USA)
- Sartorius (Germany)
- Thermo Fisher Scientific (USA)
- Danaher (USA)
- Endress+Hauser (Switzerland)
- Yokogawa Electric (Japan)
- Honeywell (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Siemens (Germany) | |||||||
| Emerson (USA) | |||||||
| ABB (Switzerland) | |||||||
| Rockwell Automation (USA) | |||||||
| Sartorius (Germany) | |||||||
| Thermo Fisher Scientific (USA) | |||||||
| Danaher (USA) | |||||||
| Endress+Hauser (Switzerland) | |||||||
| Yokogawa Electric (Japan) | |||||||
| Honeywell (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Brooks Instrument | January 2026 | Brooks Instrument launched a non-invasive clamp-on ultrasonic flow meter integrated with EtherNet/IP for upstream and downstream bioprocessing applications. This device provides real-time visibility, advanced diagnostics, and plug-and-play integration for automated skid systems, enhancing process control and measurement efficiency in biopharmaceutical production environments. |
| Sartorius Stedim Biotech | June 2025 | Sartorius Stedim Biotech finalized a major expansion at its Aubagne facility in France, nearly doubling its cleanroom and laboratory footprint. The project integrates automated production and logistics infrastructure while scaling research and development operations to advance innovative bioprocess solutions and support future manufacturing growth. |
| Sartorius | January 2025 | Sartorius partnered to establish an advanced biomanufacturing laboratory on a university campus by supplying key equipment. The infrastructure is designed to support biotherapeutic development, strengthen regional bioprocessing capabilities, and expand access to treatments for chronic conditions. |
| Getinge | December 2024 | Getinge established a Swedish partnership with 908 Devices to integrate the MAVEN system into Getinge bioreactors. This technical integration facilitates continuous, real-time monitoring and automated control of glucose and lactate levels within cell cultures, advancing bioprocess monitoring capabilities. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Bioprocess Automation Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Automation Architecture | Standalone Automation Systems, Distributed Control Systems, Integrated Process Automation Platforms |
| Manufacturing Scale | Laboratory & Discovery Scale, Pilot Scale, Commercial Production Scale |
| Procurement Model | Direct Procurement, System Integrator Procurement, Distributor-Based Procurement |
Bioprocess Automation Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Digital Biomanufacturing Adoption Roadmap |
|
| Automation Vendor Switching & Migration Dynamics |
|
| Bioprocess Workforce & Skills Transformation |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How much revenue does the bioprocess automation market generate?
What is the projected value of the bioprocess automation industry by 2036?
How is the shift toward continuous bioprocessing influencing automation adoption?
How are AI and digital twins changing bioprocess optimization priorities?
Why does process automation hardware hold the largest share of the bioprocess automation market?
How are software and control systems creating new opportunities in bioprocess automation?
What makes North America the largest market for bioprocess automation?
What is accelerating bioprocess automation adoption across Asia Pacific?
Which companies are driving growth in the bioprocess automation landscape?
Our Clients
"The team at Fundamental Business Insights & Consulting demonstrated a commitment to excellence, not only in the quality of the report but also in their client-centric approach."
FANUC
"The level of detail in the market segmentation provided were particularly noteworthy. The detailed country-level insights were also very helpful."
B&R Industrial Automation GmbH
"The consultant took the time to understand our specific business objectives, ensuring that the reports were tailored to address our unique challenges and opportunities."
KUKA SE & Co. KGaA
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Industrial Automation & Equipment Research Team at Fundamental Business Insights, a dedicated research group specializing in industrial automation technologies, manufacturing systems, and industrial equipment markets. Our analysts continuously monitor advancements in factory automation, robotics, industrial IoT (IIoT), smart manufacturing, process optimization, equipment modernization, supply chain developments, industrial safety standards, and evolving digital transformation initiatives across manufacturing industries to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with equipment manufacturers, automation solution providers, system integrators, industrial end users, distributors, and industry experts, along with company annual reports, regulatory publications, government industrial statistics, industry associations, technical standards, engineering publications, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook